Acurx Pharmaceuticals, Inc.
ACXP
$0.4791
-$0.0872-15.40%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -20.76% | 20.53% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -22.74% | -1.41% | |||
| Operating Income | 22.74% | 1.41% | |||
| Income Before Tax | 22.74% | 1.41% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 22.74% | 1.41% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 22.74% | 1.41% | |||
| EBIT | 22.74% | 1.41% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 34.69% | 4.70% | |||
| Normalized Basic EPS | 34.76% | 4.73% | |||
| EPS Diluted | 34.69% | 4.70% | |||
| Normalized Diluted EPS | 34.76% | 4.73% | |||
| Average Basic Shares Outstanding | 18.36% | 3.46% | |||
| Average Diluted Shares Outstanding | 18.36% | 3.46% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||